Ganetespib, a selective inhibitor may be a potent drug for the treatment of triple-negative breast cancer (TNBC), based on the results of small preclinical studies. Specifically, ganetespib effectively regulated several key proteins involved in tumor growth and metastasis, according to results published on-line in the Journal of Molecular Medicine and in Clinical Cancer Research:
The results demonstrate that inhibition of a wide collection of protein targets, including HIF-1alpha, correlate with potent effects on TNBC tumor cell viability and metastasis when ganetespib is administered alone or when with routinely used chemotherapy drugs for treatment of TNBC, including doxorubicin, paclitaxel, and docetaxel. Ganetespib is particularly effective against the protein HIF-1alpha, a major regulator of multiple tumor growth properties, including angiogenesis (tumor blood vessel development), metastasis (cancer spread), metabolism, cancer stem cell maintenance, and invasion.
No comments:
Post a Comment